Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP, Chief Business Officer

EVP & General Counsel

EVP, Head of Development & CMO

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	acquired	Premium	Premium	Premium	-
2024-03-08	Premium	sold	Premium	Premium	Premium	-
2024-02-08	Premium	bought	Premium	Premium	Premium	-
2024-02-08	Premium	bought	Premium	Premium	Premium	-
2024-02-08	Premium	bought	Premium	Premium	Premium	-
2024-01-05	Premium	acquired	Premium	Premium	Premium	-
2024-01-05	Premium	acquired	Premium	Premium	Premium	-
2023-12-15	Premium	sold	Premium	Premium	Premium	EVP, Chief Business Officer
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-10-05	Premium	acquired	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-09-13	Premium	sold	Premium	Premium	Premium	-
2023-07-05	Premium	acquired	Premium	Premium	Premium	-
2023-07-05	Premium	acquired	Premium	Premium	Premium	-
2023-06-07	Premium	sold	Premium	Premium	Premium	-
2023-06-07	Premium	sold	Premium	Premium	Premium	-
2023-06-06	Premium	sold	Premium	Premium	Premium	-
2023-06-06	Premium	sold	Premium	Premium	Premium	-
2023-05-26	Premium	sold	Premium	Premium	Premium	-
2023-05-26	Premium	sold	Premium	Premium	Premium	-
2023-05-25	Premium	sold	Premium	Premium	Premium	-

SANA - Sana Biotechnology, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for SANA